Loading...
XNAS
ANIK
Market cap138mUSD
Dec 05, Last price  
9.60USD
1D
1.16%
1Q
7.38%
Jan 2017
-80.39%
Name

Anika Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ANIK chart
P/E
P/S
1.15
EPS
Div Yield, %
Shrs. gr., 5y
0.48%
Rev. gr., 5y
0.91%
Revenues
120m
-28.05%
29,835,00026,840,61430,829,82135,779,78740,135,70455,556,59464,778,63571,358,50575,081,154105,594,83992,999,000103,379,000113,420,000105,555,000114,610,000130,457,000147,794,000156,236,000166,662,000119,907,000
Net income
-56m
L-31.79%
5,893,0004,604,2166,035,2543,629,1953,687,5674,315,9958,466,68011,757,46020,574,52138,319,47930,758,00032,547,00031,816,00018,722,00027,193,000-23,982,0004,134,000-14,859,000-82,667,000-56,385,000
CFO
5m
P
6,452,0002,001,1724,492,6423,407,2313,094,7057,853,46110,173,13410,548,67725,165,00139,978,37539,064,00023,801,00040,812,00034,918,00037,005,00013,065,0008,397,0004,409,000-1,788,0005,403,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
IPO date
May 16, 1985
Employees
345
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT